ARCT — Arcturus Therapeutics Holdings Inc.

Summary of Arcturus Therapeutics Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Year-over-year revenue decreased by $70.3 million annually and $15.6 million quarterly, primarily due to reduced activity in the CSL collaboration and fewer development milestones as the Costave vaccine was commercialized.
• Expenses: Research and development expenses fell by $83.0 million annually and $19.3 million quarterly, attributed to lower manufacturing and clinical costs related to the LUNAR-COV19 program transitioning to commercial status. General and administrative expenses decreased by $6.7 million annually but increased by $1.6 million quarterly due to accelerated employee stock options.
• Cash Position: As of December 31, 2025, cash, cash equivalents, and restricted cash totaled $232.8 million, down from $293.9 million a year prior. The company has extended its cash runway into Q2 2028.

2. Strategic Updates and Business Highlights

• Pipeline Progress:
  • ARCT-032 (Cystic Fibrosis): Phase II trial is set to begin in H1 2026, focusing on a 12-week study with 20 participants. The trial aims to evaluate safety and early clinical benefits, including lung function and quality of life metrics.
  • ARCT-810 (OTC Deficiency): Moving towards pivotal development with Type C regulatory meetings scheduled for H1 2026 to clarify the clinical strategy for both adult and pediatric populations.
  • Costave (COVID-19 Vaccine): Received approval from the U.K. Medicines and Healthcare Products Regulatory Agency for use in adults.
  • ARCT-2304 (Influenza Vaccine): Completed Phase I study showing durable immune response across all doses, reinforcing the STARR® sa-mRNA platform's efficacy.

3. Forward Guidance and Outlook

• The company anticipates generating meaningful clinical data from the ARCT-032 program in 2026 and is focused on achieving multiple near-term milestones in its therapeutic programs. The management expressed confidence in their financial position and the ability to fund ongoing clinical trials.

4. Bad News, Challenges, or Points of Concern

• Declining Revenue: The significant drop in revenue from collaborations raises concerns about the sustainability of income streams.
• Regulatory Challenges: The ongoing discussions with regulatory authorities regarding the OTC program's pivotal trial design highlight potential hurdles in gaining approval.
• Market Competition: The competitive landscape for both cystic fibrosis and OTC deficiency treatments remains a concern, particularly as companies vie for similar patient populations.

5. Notable Q&A Insights

• Study Design Optimizations: The upcoming 12-week CF study will include more stringent baseline stability criteria and additional quality of life measures to enhance the reliability of results.
• Dosing Flexibility: There is a possibility to adjust dosing during the study based on ongoing data collection, with a focus on maintaining cost-effectiveness.
• Regulatory Engagement: The company is actively preparing for Type C meetings with the FDA to clarify endpoints and study designs for the OTC program, indicating a proactive approach to regulatory challenges.
• Patient Enrollment Strategy: The company is enhancing its patient recruitment strategy by expanding sites internationally, particularly in regions with a higher prevalence of specific CF mutations.

Overall, while Arcturus Therapeutics is making progress in its clinical programs and maintaining a solid financial position, it faces challenges related to declining revenues and regulatory hurdles that could impact its future growth and development.